Decreased Serum Level of Interleukin-19 in Iranian Patients with Breast Cancer
Background: Interleukin-19, a member of the interleukin-10 family of cytokines, contributes to breast cancer pathogenesis. High interleukin-19 expression in breast tumor tissues is associated with poor clinical outcome. This study aimed to assess the changes in serum level of interleukin-19 in br...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Shiraz University of Medical Sciences
2015-10-01
|
| Series: | Middle East Journal of Cancer |
| Subjects: | |
| Online Access: | http://mejc.sums.ac.ir/index.php/mejc/article/view/338/225 |
| Summary: | Background: Interleukin-19, a member of the interleukin-10 family of cytokines,
contributes to breast cancer pathogenesis. High interleukin-19 expression in breast
tumor tissues is associated with poor clinical outcome. This study aimed to assess
the changes in serum level of interleukin-19 in breast cancer patients in comparison
with normal women and its association with the clinicopathological parameters of
this disease.
Methods: Enzyme-linked immunosorbent assay was used to analyze serum
levels of interleukin-19 in 116 women with breast cancer before chemotherapy or
radiotherapy, and in 60 healthy age-matched women without any acute or chronic
diseases or family history of cancer.
Results: There were significantly lower serum interleukin-19 levels in breast cancer
patients (median: 27.3 pg/ml; range: 10.5-2443.6 pg/ml) compared to healthy
controls (median: 35.1 pg/ml; range: 10.9-13676.6 pg/ml; P<0.01). Compared to the
healthy control group, the decrease in serum interleukin-19 concentration was seen
in all breast cancer stages. However the decrease was only significant for stage III
(P=0.02). We found no significant association between serum interleukin-19 levels
and stage, grade, lymph node involvement or other clinicopathological variables of
the disease. However, when compared to the healthy control group, we found
significantly decreased serum interleukin-19 levels in patients with involved lymph
nodes (P<0.01) or tumor size greater than 2 cm (P=0.01).
Conclusion: There were significantly decreased interleukin-19 levels in breast
cancer patients compared to the healthy control group. We observed no association
between serum interleukin-19 levels and clinicopathological parameters in breast
cancer patients. |
|---|---|
| ISSN: | 2008-6709 2008-6687 |